Search
MiMedx Group Inc
MDXGAdd to Watchlist
3.680USD
+0.070+1.94%
Close 06/18, 16:00（ET）Quotes delayed by 15 min
548.07MMarket Cap
17.71P/E TTM
Earnings Forecast
Currency: USD Updated: 2026-06-17The current earnings forecast score of MiMedx Group Inc is 8.00, ranking 163 out of 388 in the Biotechnology & Medical Research industry. The average price target is 12.00, with a high of 13.00 and a low of 12.00.
Analyst Rating
Based on
6
analysts
Buy
Current Rating
6.500
Target Price
+76.63%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
560
Total
5
Median
6
Average
Company name
Ratings
Analysts
MiMedx Group Inc
MDXG
6
CRISPR Therapeutics AG
CRSP
27
Ionis Pharmaceuticals Inc
IONS
27
Beigene Ltd
ONC
27
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
25
1
2
3
...
112
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
FAQs
What is MiMedx Group Inc's expected revenue for the next quarter?
MiMedx Group Inc's expected revenue is 63.46M.
What is MiMedx Group Inc's price target?
Analysts forecast that MiMedx Group Inc's price target is USD 12.00, with the highest forecast at USD 13.00 and the lowest forecast at USD 12.00.
How have MiMedx Group IncMDXG's recent earnings per share performed?
The market expectation was USD -0.07, while MiMedx Group IncMDXG's earnings per share (EPS) for the previous quarter was USD 0.10. EPS for the next quarter is expected at USD -0.04.
What is the analyst rating for MiMedx Group Inc?
Based on the ratings of MiMedx Group Inc's stock from 6 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.
